	US 11,987,805 B2
	Attb cell line, transgenic cell lines derived therefrom, and methods of making the same
William R. Jacobs, Jr., Bronx, NY (US); Lawrence Leung, Flushing, NY (US); Regy Lukose, Flanders, NJ (US); and Anna Paula de Oliveira, Bronx, NY (US)
Assigned to ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, NY (US)
Filed by Albert Einstein College of Medicine, Bronx, NY (US)
Filed on Sep. 24, 2021, as Appl. No. 17/484,476.
Claims priority of provisional application 63/082,701, filed on Sep. 24, 2020.
Prior Publication US 2022/0090146 A1, Mar. 24, 2022
Int. Cl. C12N 15/01 (2006.01); C07K 14/35 (2006.01); C12N 7/00 (2006.01); C12N 9/22 (2006.01); C12N 15/09 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01); C12Q 1/70 (2006.01)

CPC C12N 15/907 (2013.01) [C07K 14/35 (2013.01); C12N 7/00 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12Q 1/70 (2013.01); C12N 2310/20 (2017.05); C12N 2710/16652 (2013.01); C12N 2800/80 (2013.01)]

44 Claims

1. A genetically modified mammalian cell comprising a recombination sequence inserted in a target locus on a chromosome of the Vero cell genome, wherein the recombination sequence comprises a Bxb1 attB sequence from Mycobacterium smegmatis wherein the mammalian cell is a Vero cell and the target locus comprises adeno-associated virus integration site 1 (AAVS1) on chromosome 6 of the Vero cell genome, wherein the AAVS1 locus comprising the recombination sequence has the 4 kilobase sequence of SEQ ID NO:22.